- Home
- INDV vs GNTX Comparison
INDV vs GNTX Comparison
Compare INDV & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INDV | GNTX |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | INDV | GNTX |
|---|---|---|
| Price | $34.85 | $22.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $26.60 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 06-08-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | ★ 8100.00 | N/A |
| EPS | ★ 1.67 | 1.00 |
| Revenue | $1,239,000,000.00 | ★ $2,534,268,965.00 |
| Revenue This Year | N/A | $6.89 |
| Revenue Next Year | N/A | $4.58 |
| P/E Ratio | ★ $21.37 | $22.46 |
| Revenue Growth | 4.29 | ★ 9.55 |
| 52 Week Low | $22.30 | $20.48 |
| 52 Week High | $42.81 | $29.01 |
Technical Indicators
Market Signals| Indicator | INDV | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 37.97 |
| Support Level | $32.06 | $21.26 |
| Resistance Level | $35.54 | $22.26 |
| Average True Range (ATR) | 0.86 | 0.44 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 55.79 | 17.55 |
Price Performance
Historical ComparisonAbout INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.